Immunocore Ltd., a T Cell Receptor (TCR) biotechnology company, has entered into a new partnership with Genentech, a member of the Roche Group, to expand an existing discovery collaboration to co-develop Immunocore’s IMC-C103C candidate, an ImmTAC molecule targeting tumors that express the protein MAGE-A4 (Melanoma-Associated Antigen A4). Immunocore will lead the first-in-human trial to establish safety and preliminary efficacy of IMC-C103C as both monotherapy and in combination with Genentec...